Health Problems

idecabtagene vicleucel

idecabtagene vicleucel U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE) September 22, 2020 — Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. […]